NFKB1 and glioblastoma: Although a number of small molecule inhibitors of the NFκB pathway, mainly inhibitors of IKK proteins, are already available, more specific inhibitors of IKKβ and other upstream kinases need to reach clinical studies to prove their efficacy in GBM patients.